A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicin

References

• Davis H L, Davis T E. Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treat Rep 1979; 63: 809–815
   PubMedGoogle Scholar
• Skipper H E, Schabel F M, Jr, Mellett L B, Montgomery J A, Wilkoff L J, Lloyd H H, Brockman R W. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970; 54: 431–450
   PubMedGoogle Scholar
• Minow R A, Benjamin R S, Lee E T, Gottlieb J A. Adriamycin cardiomyopathy—risk factors. Cancer 1977; 39: 1397–1402
   PubMed Web of Science ®Google Scholar
• Von Hoff D D, Layard M W, Basa P, Davis H L, Jr, Von Hoff A L, Rozencweig M, Muggia F M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–717
   PubMed Web of Science ®Google Scholar
• Legha S S, Benjamin R S, Mackay B, Yap H Y, Wallace S, Ewer M, Blumenschein G R, Freireich E J. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982; 49: 1762–1766
   PubMed Web of Science ®Google Scholar
• Langebrake C, Reinhardt D, Ritter J. Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf 2002; 25: 1057–1077
   PubMed Web of Science ®Google Scholar
• Bielack S S, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873–882
   PubMedGoogle Scholar
• Bielack S S, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?. Eur J Cancer 1996; 32A: 1652–1660
   PubMed Web of Science ®Google Scholar
• Robert J. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?. Cancer Drug Deliv 1987; 4: 191–199
   PubMedGoogle Scholar
• Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio M T, Calabro R. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 2005; 7: 67–76
   PubMedGoogle Scholar
• Kishi S, Goto N, Nakamura T, Ueda T. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Cancer Res 1999; 59: 2629–2634
   PubMed Web of Science ®Google Scholar
• Nishimura M, Kumamoto Y, Shibuya A, Hirose T, Tsukamoto T, Ohya S. [An in vitro study on the treatment of complicated cystitis using an automatic simulator]. Kansenshogaku Zasshi 1990; 64: 1004–1012
   PubMedGoogle Scholar
• Benjamin R S, Riggs C E, Jr, Bachur N R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977; 37: 1416–1420
   PubMed Web of Science ®Google Scholar
• Dorr R T, Bozak K A, Shipp N G, Hendrix M, Alberts D S, Ahmann F. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. Cancer Res 1988; 48: 5222–5227
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994; 75: 426–433
   PubMed Web of Science ®Google Scholar
• Haddad J, Decker M L, Hsieh L C, Lesch M, Samarel A M, Decker R S. Attachment and maintenance of adult rabbit cardiac myocytes in primary cell culture. Am J Physiol 1988; 255: C19–C27
   PubMed Web of Science ®Google Scholar
• VanWinkle W B, Snuggs M B, Buja L M. Cardiogel: a biosynthetic extracellular matrix for cardiomyocyte culture. In Vitro Cell Dev Biol Anim 1996; 32: 478–485
   PubMed Web of Science ®Google Scholar
• Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration – time product. Cancer Chemother Pharmacol 1988; 21: 185–190
   PubMed Web of Science ®Google Scholar
• Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 1989; 49: 3823–3828
   PubMed Web of Science ®Google Scholar
• Chervinsky D S, Wang J J. Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study. J Med 1976; 7: 63–79
   PubMedGoogle Scholar
• Bachur N R, Steele M, Meriwether W D, Hildebrand R C. Cellular pharmocodynamics of several anthrocycline antibiotics. J Med Chem 1976; 19: 651–654
   PubMed Web of Science ®Google Scholar
• Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit 1989; 11: 140–148
   PubMed Web of Science ®Google Scholar
• Claycomb W C, Bradshaw H D, Jr. Acquisition of multiple nuclei and the activity of DNA polymerase alpha and reinitiation of DNA replication in terminally differentiated adult cardiac muscle cells in culture. Dev Biol 1983; 99: 331–337
   PubMed Web of Science ®Google Scholar
• Oparil S, Bishop S P, Clubb F J, Jr. Myocardial cell hypertrophy or hyperplasia. Hypertension 1984; 6: 38–43
   Web of Science ®Google Scholar
• Iwamoto Y, Hansen I L, Porter T H, Folkers K. Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 1974; 58: 633–638
   PubMed Web of Science ®Google Scholar
• Doroshow J H, Locker G Y, Myers C E. Experimental animal models of adriamycin cardiotoxicity. Cancer Treat Rep 1979; 63: 855–860
   PubMedGoogle Scholar
• Seraydarian M W, Artaza L, Goodman M F. Adriamycin: effect on mammalian cardiac cells in culture. I. Cell population and energy metabolism. J Mol Cell Cardiol 1977; 9: 375–382
   PubMed Web of Science ®Google Scholar
• Gosalvez M, van Rossum G D, Blanco M F. Inhibition of sodium-potassium-activated adenosine 5′-triphosphatase and ion transport by adriamycin. Cancer Res 1979; 39: 257–261
   PubMed Web of Science ®Google Scholar
• Kawasaki N, Lee J D, Shimizu H, Ueda T. Long-term 1-carnitine treatment prolongs the survival in rats with adriamycin-induced heart failure. J Card Fail 1996; 2: 293–299
   PubMedGoogle Scholar
• Billingham M E, Mason J W, Bristow M R, Daniels J R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–872
   PubMedGoogle Scholar
• Jaenke R S, Fajarado D F. Adriamycin-induced myocardial lesions. Report of a workshop. Am J Surg Pathol 1977; 1: 55–60
   PubMed Web of Science ®Google Scholar
• Arola O J, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki L M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000; 60: 1789–1792
   PubMed Web of Science ®Google Scholar
• Haq M M, Legha S S, Choksi J, Hortobagyi G N, Benjamin R S, Ewer M, Ali M. Doxorubicin-induced congestive heart failure in adults. Cancer 1985; 56: 1361–1365
   PubMed Web of Science ®Google Scholar
• Legha S S, Benjamin R S, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S L, Blumenschein G R, Freireich E J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–139
   PubMed Web of Science ®Google Scholar